Impact of Obstructive Sleep Apnea on Maternal Health and GDM

Obstructive sleep apnea (OSA) is a condition that is increasingly recognized during pregnancy, particularly among women with gestational diabetes mellitus (GDM). This is significant because both OSA and GDM are associated with adverse maternal and fetal outcomes. The study in question aimed to investigate how specific characteristics of OSA, particularly during the third trimester, influence perinatal outcomes in women diagnosed with GDM. Understanding these relationships is crucial for improving maternal and fetal health. In this prospective study involving 89 women with GDM, researchers conducted polysomnography to assess OSA and measured insulin resistance using indices such as HOMA-IR and QUICKI. They also analyzed several biomarkers, including insulin-like growth factor-1 (IGF-1), resistin, and free fatty acids. While the overall perinatal outcomes did not show significant differences due to OSA, specific features such as REM-OSA, OSA during supine position, and an oxygen desaturation index (ODI) of ≥1 h^-1 were linked to negative impacts on neonatal birth weight and length. Notably, apnea duration emerged as an independent predictor of birth weight, indicating that longer apnea episodes could lead to lower birth weights. The findings suggest that women with OSA exhibited higher insulin resistance compared to those without. This was evidenced by an inverse relationship between insulin resistance and both total sleep time and REM sleep duration. Additionally, IGF-1 levels were elevated in women with OSA and demonstrated significant predictive value for OSA diagnosis, as indicated by the area under the curve (AUC) in receiver operating characteristic (ROC) analysis. These insights underline the importance of monitoring OSA characteristics in pregnant women, especially those with GDM, to mitigate potential risks to fetal growth. For individuals managing their metabolic health, particularly pregnant women with GDM, it is essential to be aware of the potential implications of OSA. Regular sleep assessments and monitoring for OSA symptoms can help in early identification and management, potentially improving both maternal and fetal outcomes. Furthermore, lifestyle interventions that promote better sleep hygiene and weight management may also play a role in reducing the severity of OSA and its associated risks. This study connects to several biomarkers relevant to metabolic health, including HOMA-IR, which measures insulin resistance, and IGF-1, which may serve as a potential biomarker for OSA in this population. Monitoring these biomarkers can provide valuable insights into the metabolic status of pregnant women and help guide interventions. In conclusion, while OSA did not significantly affect overall perinatal outcomes, specific characteristics of OSA were associated with adverse neonatal growth metrics. The elevated insulin resistance in women with OSA highlights the need for targeted interventions. Future research should continue to explore the complex interactions between OSA, GDM, and fetal outcomes, emphasizing the importance of comprehensive care for pregnant women.